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Abstract 
Background:  Prediction of diagnosis of ventilator‑associated pneumonia (VAP) remains difficult. Our aim was to 
assess the value of biomarker kinetics in VAP prediction.
Methods: We performed a prospective, multicenter, observational study to evaluate predictive accuracy of bio‑
marker kinetics, namely C‑reactive protein (CRP), procalcitonin (PCT), mid‑region fragment of pro‑adrenomedullin 
(MR‑proADM), for VAP management in 211 patients receiving mechanical ventilation for >72 h. For the present analy‑
sis, we assessed all (N = 138) mechanically ventilated patients without an infection at admission. The kinetics of each 
variable, from day 1 to day 6 of mechanical ventilation, was assessed with each variable’s slopes (rate of biomarker 
change per day), highest level and maximum amplitude of variation (Δmax).
Results: A total of 35 patients (25.4 %) developed a VAP and were compared with 70 non‑infected controls (50.7 %). 
We excluded 33 patients (23.9 %) who developed a non‑VAP nosocomial infection. Among the studied biomarkers, 
CRP and CRP ratio showed the best performance in VAP prediction. The slope of CRP change over time (adjusted 
odds ratio [aOR] 1.624, confidence interval [CI]95% [1.206, 2.189], p = 0.001), the highest CRP ratio concentration (aOR 
1.202, CI95% [1.061, 1.363], p = 0.004) and Δmax CRP (aOR 1.139, CI95% [1.039, 1.248], p = 0.006), during the first 6 days of 
mechanical ventilation, were all significantly associated with VAP development. Both PCT and MR‑proADM showed a 
poor predictive performance as well as temperature and white cell count.
Conclusions: Our results suggest that in patients under mechanical ventilation, daily CRP monitoring was useful in 
VAP prediction.
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Background
Ventilator-associated pneumonia (VAP) is usually caused 
by bacteria and is the most common serious intensive 
care unit (ICU)-acquired infection in patients undergo-
ing invasive mechanical ventilation [1]. The widespread 
implementation of several preventive measures is, at least 
in part, associated with the observed decrease in VAP 
incidence [2].
One of the most challenging problems in VAP is its 
correct identification, resulting from the lack of a “gold 
standard” method of diagnosis [1]. The commonly used 
criteria are too sensitive but poorly specific [3]; as a 
result, up to 50 % of patients diagnosed with VAP do not 
have the condition and up to 30 % of cases of VAP are not 
correctly identified [4].
The accuracy of several biomarkers in the diagnosis and 
management of infection, namely VAP, have been evalu-
ated repeatedly [5–9] with soluble triggering receptor 
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expressed on myeloid cells (sTREM-1), C-reactive pro-
tein (CRP) and procalcitonin (PCT) being the most fre-
quently studied.
The majority of the published studies assessed the 
usefulness of a single biomarker measurement in VAP 
diagnosis [3, 10]. Few have studied the value of serial 
measurements in the assessment of VAP, either before 
the diagnosis or after initiation of antibiotic therapy. In 
addition, these studies on biomarkers present discord-
ant results [11–14], not achieving sufficient specificity or 
sensitivity to be routinely employed in clinical practice.
Our hypothesis was that the course of plasma concen-
trations of biomarkers after endotracheal intubation and 
invasive mechanical ventilation could be useful in VAP 
prediction. With that purpose, we assessed the predictive 
performance of kinetics of several biomarkers, namely 
CRP, PCT and MR-proADM, in all non-infected patients 
during the first 6 days of mechanical ventilation. Besides 
we also assessed the diagnostic performance of a single 
biomarker measurement at the day of VAP diagnosis.
Methods
Study design
The BioVAP study (biomarkers in the diagnosis and 
management of VAP) is a prospective, multicenter, 
observational study, designed to evaluate the additional 
information biomarkers can bring in the clinical decision-
making process of VAP at the bedside (NCT02078999). 
The ICU recruitment was by direct invitation with no 
financial incentive. Local hospital ethics committees 
approved the study design, and written informed consent 
was obtained from all patients or their legally authorized 
surrogates in accordance with local requirements.
Study subjects
During the study period (September 2008 till September 
2010), all patients admitted to the participating ICU were 
screened for inclusion if they were mechanically venti-
lated for >72 h. A total of 211 included adult (>18 years) 
patients were divided into three groups: (1) non-infected, 
(2) pulmonary infection and (3) non-pulmonary infection 
(for details, see Fig. 1; Additional file 1). For each patient, 
only the first ICU admission and the first VAP episode 
were included in the study.
Data collection and management
Data collection included demographic data and comor-
bid diseases (for data management, see Additional 
file 1). Clinical and laboratory data, namely the reason of 
mechanical ventilation at ICU admission, were recorded. 
The Simplified Acute Physiology Score (SAPS) II [15] was 
calculated from the worst values within the first 24 h after 
ICU admission. Microbiological and clinical infectious 
data were reported as well as the antibiotics prescribed, 
their changes and the duration of therapy. Organ dys-
functions were evaluated at ICU admission and during 
the duration of mechanical ventilation according to the 
Sequential Organ Failure Assessment (SOFA) score [16].
Day 1 (D1) was considered the day of initiation of inva-
sive mechanical ventilation. Patients were monitored till 
D21, the day of successful weaning and extubation, the 
day of a non-VAP infection or the day of clinical diag-
nosis of VAP whatever arrived first (for definitions see 
Additional file 1).
The following clinical variables were collected daily: 
mechanical ventilation parameters at 08:00, American 
College of Chest Physicians/Society of Critical Care 
Medicine (ACCP/SCCM) consensus conference on 
sepsis criteria, simplified Clinical Pulmonary Infection 
Score (CPIS) [17, 18], SOFA score, daily registry of the 
renal support therapy, surgery (type and reason), ster-
oids (drug, dose and reason), any ICU-acquired infection 
other than VAP, antibiotic therapy if applied.
Blood samples were obtained from an arterial line at 
ICU admission and subsequently daily every morning for 
the routine assessment of CRP, PCT, MR-proADM and 
arterial blood gases. In all patients, a quantitative tra-
cheal aspirate (QTA) was performed at ICU admission 
and subsequently twice a week (Mondays–Thursdays or 
Tuesdays–Fridays).
Patients were followed up till death or ICU discharge as 
well as hospital discharge. At 90th day, a telephonic inter-
view was performed for outcome assessment.
For the present analysis, we compared biomarker kinet-
ics of VAP patients and non-infected controls during the 
first 6 days of mechanical ventilation as well as at the day 
of VAP diagnosis. All VAP have microbiological docu-
mentation (for definitions, see Additional file 1).
Statistical analysis
Continuous variables were expressed as mean and stand-
ard deviation (SD) or median and interquartile range 
(IQR) if the distribution was clearly asymmetric. Com-
parisons between groups were performed with two-tailed 
unpaired Student’s t test or Mann–Whitney U tests for 
continuous variables according to data distribution. Fish-
er’s exact test and Chi-square test were used to carry out 
comparisons between categorical variables as appropriate.
In addition to CRP evaluation, we also assessed the 
relative changes in CRP concentration and the CRP ratio. 
The relative changes were calculated in relation to D1 
CRP concentration.
Time-dependent analysis of different variables from D1 
to D6 of mechanical ventilation was performed with gen-
eral linear models univariate repeated measures analysis 
using a split-plot design approach.
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For the statistical analysis of the patient’s infectious 
status, VAP versus non-infected controls, as function of 
a longitudinal covariate, obtained from the six measure-
ments of the variables of interest between D1 and D6 
(CRP, PCT, MR-proADM, white cell count (WCC), tem-
perature and CPIS), we used a two-step approach as pre-
viously described elsewhere [19] (for additional details, 
see Additional file  1), in order to evaluate the slope of 
each variable over time (see Additional file 2: Figure S1).
Receiver operating characteristics curves (ROC) were 
plotted for the day of VAP diagnosis of the studied vari-
ables. The accuracy of these variables was assessed calcu-
lating its area under the curve (AUC), assessment of the 
best cutoff value, sensitivity and specificity calculation as 
well as the likelihood ratios.
Data were analyzed using PASW version 20.0 for MAC 
(SPSS, Chicago, IL, USA) and R (R Development Core 
Team: A Language and Environment for Statistical Com-
puting. Vienna, Austria: 2005). Adjusted odds ratios (OR) 
with 95  % confidence interval (CI) were computed. All 
statistics were two-tailed, and significance level was set at 
0.05.
Results
During the study period, a total of 211 patients were 
included in the BioVAP study (Fig.  1). For the present 
analysis, we assessed all non-infected mechanically ven-
tilated patients (N = 138). A total of 35 patients (25.4 %) 
developed VAP, 70 (50.7 %) had no infection and did not 
receive antibiotics (controls), and 33 (23.9 %) developed 
another non-VAP nosocomial infection. The last group 
was excluded.
The baseline patients’ characteristics are presented 
in Table  1. At the day of initiation of mechanical venti-
lation, patients that develop a VAP and non-infected 
controls presented similar characteristics, with the two 
exceptions; at admission, in VAP group, CRP was sig-
nificantly lower and SOFA score was significantly higher 
when compared with controls. From the 35 VAP epi-
sodes (35/211—25.4  %), with 41 bacterial isolates (see 
Fig. 1 Flowchart of patients undergoing mechanical ventilation during the study period
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Table 1 Baseline characteristics of all patients mechanically ventilated for non-infectious reasons
Total (N = 138) VAP (N = 35) No infection (N = 70) p
Male, N (%) 93 (67.4 %) 26 (74.3 %) 41 (58.6 %) 0.116
Age (years) 59.8 ± 18.4 57.9 ± 16.2 60.6 ± 20.5 0.501
SAPS II 49.1 ± 18.4 52.6 ± 18.3 49.8 ± 19.0 0.479
SOFA 7.2 ± 3.0 8.1 ± 2.9 6.8 ± 2.9 0.045
CPIS 2.6 ± 1.9 2.7 ± 2.0 2.7 ± 1.9 0.971
Cause of admission, N (%) 0.581
 Medical 96 (69.6 %) 25 (71.4 %) 50 (71.4 %)
 Trauma 2 (1.4 %) 8 (22.9 %) 11 (15.7 %)
 Elective surgery 27 (19.6 %) 0 1 (1.4 %)
 Emergency surgery 13 (9.4 %) 2 (5.7 %) 8 (11.4 %)
Comorbidities, N (%)
 COPD 19 (13.8 %) 7 (20.0 %) 6 (8.6 %) 0.119
 Steroids 1 (0.7 %) 1 (1.4 %)
 Diabetes 19 (13.8 %) 3 (8.6 %) 12 (17.1 %) 0.375
 Immunosuppression 3 (2.2 %) 1 (1.4 %)
 CHF 23 (16.7 %) 3 (8.6 %) 14 (20.0 %) 0.167
 CLD 1 (0.7 %) 1 (2.9 %)
 CRF 9 (6.5 %) 3 (8.6 %) 6 (8.6 %) 1.0
 HIV 3 (2.2 %) 1 (2.9 %) 2 (2.9 %) 1.0
Admission diagnosis, N (%) 0.501
 CVA 16 6 10
 AECB 6 2 4
 Decompensated CHF 17 5 12
 TBI 19 10 9
 Others 28 14 14
Reason of MV, N (%) 0.1
 Respiratory failure 40 (29.0 %) 8 (22.9 %) 23 (32.9 %)
 Shock 17 (12.3 %) 8 (22.9 %) 5 (7.1 %)
 Coma 76 (55.1 %) 17 (48.6 %) 40 (51.7 %)
 Other 5 (3.6 %) 2 (5.7 %) 2 (2.9 %)
Tidal volume (mL) 458 [146] 488 [97] 442 [160] 0.21
Plateau pressure (cmH2O) 19 [7] 21 [9] 19 [6] 0.213
PEEP 5 [2] 5 [3] 5 [2] 0.686
PaO2/FiO2 245 [172] 245 [122] 224 [213] 0.828
CPR (mg/dL) 6.00 [8.62] 4.33 [6.20] 8.40 [9.39] 0.003
PCT (μg/L) 0.40 [1.76] 0.94 [2.37] 0.34 [1.48] 0.167
MR‑proADM (nmol/L) 1.85 [2.64] 1.70 [2.87] 1.91 [2.82] 0.470
WCC (×103/mm3) 12.46 ± 4.55 12.58 ± 4.92 11.85 ± 4.54 0.456
Temperature (°C) 36.7 ± 1.3 36.9 ± 1.3 36.4 ± 1.3 0.126
Nosocomial infectiona 68 (49.3 %)
 VAP 35 (25.4 %)
 VAT 14 (10.1 %)
 CVC bacteremia 2 (1.4 %)
 UTI 6 (4.3 %)
 Surgical infection 5 (3.6 %)
 Other 6 (4.3 %)
Duration of MV (days) 7.5 [9.8] 14.0 [8.0] 5.0 [5.5] <0.001
LOS ICU (days) 12.0 [12.0] 18.0 [12.0] 10.0 [8.5] <0.001
LOS hospital (days) 25.0 [30.3] 27.0 [31.5] 24.0 [30.5] 0.55
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Additional file  1), 18 were early VAP and 77.1  % were 
diagnosed during the first week of mechanical ventila-
tion. The duration of mechanical ventilation till the diag-
nosis of VAP was (median) 5.0 days (IQR 4.0).
Kinetics of biomarkers and inflammatory variables
Figure  2 presents the variables’ values during the study 
period from D1 to D6. The time-dependent analy-
sis of CRP and CRP ratio was significantly different 
between non-infected controls and patients that went 
on to develop a VAP (p  <  0.001 and p  <  0.001, respec-
tively). In VAP patients, we found no differences in CRP 
kinetics between early and late VAP (p =  0.304). When 
we compared CRP and CRP ratio at the different time 
points, their values were significantly higher from D5 
of mechanical ventilation onwards in VAP patients. The 
time-dependent analysis of PCT (log transform), MR-
proADM, WCC and temperature values was not signifi-
cantly different between groups (p  =  0.685, p  =  0.753, 
p = 0.681 and p = 0.835, respectively).
To study the value in VAP prediction of the kinetics of 
each variable, we evaluated the absolute changes from D1 
to D6 of mechanical ventilation assessed with the previ-
ously calculated slopes, as well the highest value and the 
Δmax.
The slope describes the rate of change per day of a 
particular variable in each patient from the beginning 
of mechanical ventilation, that is D1, till D6. Additional 
file  2: Figure S1 presents some examples of predictions 
of individual CRP slopes that describe the CRP rate of 
change per day in an individual patient. Among all the 
studied slopes (Additional file 1), only CRP and CRP ratio 
were significantly different between groups (p  =  0.001, 
p  <  0.001, respectively). The slopes of CRP and CRP 
ratio showed a reasonable diagnostic performance with a 
ROC–AUC >0.7. Besides, CRP and CRP ratio were sig-
nificantly associated with VAP prediction (Table 2). After 
adjustment for confounders, the slope of CRP was sig-
nificantly associated with VAP development (aOR 1.624, 
CI95% [1.206, 2.189], p = 0.001). The ability of the model 
to predict VAP assessed by the area under the ROC curve 
was 0.71 (CI95% [0.60; 0.82]). As an example, a patient 
with an average increase in CRP concentration of 1 mg/
dL/day from D1 till D6 of mechanical ventilation has 
62 % greater chance of having VAP when compared with 
a patient with no CRP increase. The same is shown in 
Fig. 3, with the CRP-slope calibration plot showing that 
the higher the slope, the higher the VAP probability.
We evaluated the highest value reached by a variable 
from the beginning of mechanical ventilation, that is D1, 
till D6 in VAP patients and non-infected controls. Of the 
studied variables (Additional file  1), only highest CRP 
ratio, MR-proADM and temperature were significantly 
different between groups (p < 0.001, p = 0.014, p = 0.027, 
respectively). However, only the highest value of CRP 
ratio showed a reasonable diagnostic performance with 
a ROC–AUC above 0.7. Moreover, the highest value of 
CRP ratio and MR-proADM were significantly associ-
ated with VAP prediction (Table 2). After adjustment for 
confounders, highest CRP ratio was significantly associ-
ated with VAP development (aOR 1.202, CI95% [1.061, 
1.363], p  =  0.004). The ability of the model to predict 
VAP assessed by the area under the ROC curve was 
0.75 (CI95% [0.64; 0.87]) for the highest CRP ratio. As an 
example, for each 10 % increase in the highest CRP ratio 
concentration from D1 to D6 was associated with a 20 % 
greater chance of having VAP when compared with a 
patient with no CRP ratio change. The same is shown in 
Fig. 3, with the calibration plot showing that the higher 
the highest CRP ratio, the higher the VAP probability.
The maximum delta (Δmax) evaluates the difference 
between the lowest and the highest value of each variable 
from the beginning of mechanical ventilation, that is D1, 
till D6 in VAP patients and non-infected controls. Of the 
studied variables (Additional file 1), only CRP, CRP ratio 
and MR-proADM were significantly different between 
groups (p < 0.001, p < 0.001, p = 0.01, respectively). The 
Δmax of CRP showed a good diagnostic performance with 
a ROC–AUC >0.75 but was outperformed by Δmax of 
CRP ratio with an ROC–AUC of 0.82. Besides, Δmax of 
CRP and CRP ratio was significantly associated with VAP 
prediction (Table  2). After adjustment for confounders, 
AECB acute exacerbation of chronic bronchitis, CHF chronic heart failure, CVA cerebrovascular accident, CLD chronic liver disease, COPD chronic obstructive pulmonary 
disease, simplified CPIS Clinical Pulmonary Infection Score, CRF chronic renal failure, CRP C-reactive protein, CVC central venous catheter, HIV human immunodeficiency 
virus, ICU intensive care unit, LOS length of stay, MV mechanical ventilation, MR-proADM mid-region fragment of pro-adrenomedullin, PaO2/FiO2 ratio of partial 
pressure of arterial O2 to the fraction of inspired O2, PCT procalcitonin, PEEP positive end-expiratory pressure, SAPS Simplified Acute Physiology Score, SOFA Sequential 
Organ Failure Assessment, TBI traumatic brain injury, UTI urinary tract infection, VAP ventilator-associated pneumonia, VAT ventilator-associated tracheobronchitis, 
WCC white cell count
Table 1 continued
Total (N = 138) VAP (N = 35) No infection (N = 70) p
Mortality D28, N (%) 16 (18.6) 15 (40.5) 1 (2) <0.001
Mortality D90, N (%) 20 (23.3) 15 (40.5) 5 (10.2) 0.004
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Fig. 2 Time course of biomarkers (CRP, PCT and MR‑proADM), temperature and WCC from day 1 to day 6 of mechanical ventilation in ventilator‑
associated pneumonia (VAP) patients and non‑infected controls (a CRP, b CRP ratio, c PCT, d MR‑proADM, e WCC, f temperature). Time‑dependent 
analysis of CRP, CRP ratio and CPIS was significantly different between VAP patients and controls (p < 0.001, p < 0.001 and p = 0.019, respectively). 
Some variables, namely CRP and CRP ratio, became significantly higher by day 5 in patients that will develop a VAP in comparison with controls 
(*p < 0.05). CRP C‑reactive protein, MR‑proADM mid‑region fragment of pro‑adrenomedullin, PCT procalcitonin, VAP ventilator‑associated pneumo‑
nia, WCC white cell count
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Δmax of CRP was significantly associated with VAP devel-
opment (aOR 1.139, CI95% [1.039, 1.248], p  =  0.006, 
respectively). The ability of the adjusted model to predict 
VAP assessed by the area under the ROC curve was 0.82 
(CI95% [0.73; 0.91]) for Δmax CRP. As an example, for each 
1 mg/dL increment in Δmax CRP concentration from D1 
to D6 of mechanical ventilation was associated with a 
14 % greater chance of having VAP when compared with 
a patient with no CRP concentration change.
Figure 3 also shows the calibration plots of PCT (slope, 
highest and Δmax). The inverted U-shape of the three 
curves clearly shows that the kinetics of PCT assessed by 
the slope, the highest value as well as the Δmax was not 
useful in VAP prediction that is far from the ideal linear 
correlation that is indicative of a good diagnostic marker.
Discussion
The present analysis of the BioVAP study showed that, 
among the studied biomarkers, only the kinetics of serial 
CRP measurements during the first 6 days of mechanical 
ventilation was useful in VAP prediction. We showed that 
the rate of change per day of CRP and CRP ratio, but also 
the highest value of CRP ratio and the maximum change 
in CRP and CRP ratio during the study period were all 
associated with VAP prediction. In addition, at the day of 
VAP diagnosis we showed that a single measurement of 
CRP was useful in particular to exclude VAP diagnosis, 
whereas CPIS was better to include VAP.
In our analysis, VAP and controls presented simi-
lar baseline characteristics, with the exception of CRP, 
which was higher in the control group, and SOFA score, 
which was higher in patients that developed VAP. Our 
study was not designed to assess mortality or prognosis 
of mechanically ventilated patients but to evaluate the 
predictive performance for VAP of the kinetics of differ-
ent biomarkers, that is to say, to identify patients with a 
high probability VAP, before its clinical diagnosis. To do 
so, we assessed the kinetics of several biomarkers during 
the first 6 days of mechanical ventilation to evaluate their 
performance in VAP prediction, not as risk factors [20].
In VAP, some studies have previously looked at PCT 
and/or CRP concentration changes before diagnosis. 
Luyt et  al. [13] found that PCT, either absolute values 
or concentration changes in the 5 days before diagnosis, 
had a poor diagnostic performance for late VAP. Charles 
et al. [21] showed that, within the period spanning 3 days 
before the day of diagnosis, PCT changed only in the last 
24 h but with a very good diagnostic performance. Finally, 
Table 2 Evaluation of studied variables in ventilator-associated pneumonia prediction
Variables included in the adjusted model: age, sex, SAPS II, cause of admission
Simplified CPIS Clinical Pulmonary Infection Score, CRP C-reactive protein, MR-proADM mid-region fragment of pro-adrenomedullin, OR odds ratio, PCT procalcitonin, 
ROC receiver operating characteristics, VAP ventilator-associated pneumonia, WCC white cell count
OR 95 % CI p aOR 95 % CI p
Slope
 CRP (mg/dL) 1.641 1.229–2.192 <0.001 1.624 1.206–2.189 0.001
 CRP ratio 1.516 1.021–2.250 0.039 1.480 1.060–2.067 0.021
 PCT (μg/L) 0.803 0.544–1.183 0.267 0.844 0.559–1.274 0.419
 ADM (nmol/L) 0.740 0.147–3.742 0.716 0.730 0.137–3.902 0.713
 WCC (×103/mm3) 1.182 0.807–1.729 0.391 1.225 0.809–1.855 0.338
 Temperature (°C) 0.288 0.033–2.540 0.262 0.270 0.028–2.590 0.256
Highest
 CRP (mg/dL) 1.044 1.000–1.090 0.052 1.037 0.992–1.085 0.11
 CRP ratio 1.201 1.065–1.355 0.003 1.202 1.061–1.363 0.004
 PCT (μg/L) 1.032 0.987–1.079 0.168 1.020 0.974–1.068 0.392
 ADM (nmol/L) 1.335 1.022–1.744 0.034 1.369 1.035–1.809 0.028
 WCC (×103/mm3) 1.032 0.987–1.079 0.168 1.020 0.974–1.068 0.392
 Temperature (°C) 2.043 1.170–3.536 0.012 2.053 1.126–3.744 0.019
Δmax
 CRP (mg/dL) 1.151 1.057–1.252 0.001 1.139 1.039–1.248 0.006
 CRP ratio 1.213 1.030–1.428 0.021 1.186 1.018–1.381 0.029
 PCT (μg/L) 1.036 0.984–1.089 0.178 1.023 0.971–1.078 0.399
 ADM (nmol/L) 1.395 0.964–2.020 0.078 1.372 0.943–1.996 0.099
 WCC (×103/mm3) 1.044 0.963–1.131 0.294 1.046 0.959–1.140 0.312
 Temperature (°C) 1.020 0.665–1.565 0.928 0.933 0.583–1.494 0.772
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Fig. 3 Curve of disease risk probability of ventilator‑associated pneumonia (VAP), for the possible range of kinetics of CRP concentration changes 
over time, assessed by the slope, highest value and Δmax from day 1 to day 6 of mechanical ventilation (a–c CRP, d–f PCT, respectively). Ideally, the 
line should show a linear relationship between the marker and the probability of VAP. For PCT, the same calibration plots are presented (slope, high‑
est and Δmax). CRP C‑reactive protein, VAP ventilator‑associated pneumonia
Page 9 of 11Póvoa et al. Ann. Intensive Care  (2016) 6:32 
in the diagnosis of aspiration syndromes, PCT presented 
a poor diagnostic performance in three studies [22–24], 
whereas CRP showed to be clinically helpful in the one 
study in which it was evaluated [22]. None of these stud-
ies performed an analysis of biomarker kinetics.
In our study, it was also clear that, from D1 to D6 of 
mechanical ventilation, both CRP and CRP ratio increase 
steadily in VAP group and became significantly higher 
from D5 onwards. Of the studied biomarkers, the slope 
of CRP was the individual variable most useful in VAP 
prediction. In addition, the calibration plot nicely sepa-
rates those patients with low slopes and low probability 
of VAP from those with higher slopes and higher prob-
ability. This is particularly relevant, since monitoring the 
course of a single biomarker is much easier to interpret 
than the calculation of a score.
Besides, we also evaluated a single biomarker measure-
ment on the day of VAP diagnosis. In doing so, we found 
that CRP was the best biomarker. With a similar meth-
odology, we have previously showed that CRP presented 
a good performance in VAP diagnosis, and interestingly 
found an almost equal cutoff of 9.6 mg/dL [25].
As far as we are aware, the present study is the first using 
strict inclusion criteria comparing the diagnostic per-
formance of CRP and PCT in VAP prediction. Previous 
studies comparing the diagnostic performance for infec-
tion of a single value of CRP and PCT in different clinical 
scenarios showed that, at the day of diagnosis, the AUC of 
CRP was always higher than of PCT [22, 26–31]. Similarly, 
in our study in VAP patients, CRP performed better than 
PCT, presenting a good negative likelihood ratio, mean-
ing that CRP is a good biomarker to exclude that diagno-
sis in the presence of dubious clinical manifestations. On 
the opposite, the poor diagnostic performance of PCT has 
been attributed to the relatively low virulence of the usual 
microorganisms found in VAP [8, 32] as well as being con-
sidered a compartmentalized infection [32, 33].
The MR-proADM is a novel biomarker and has not yet 
been well evaluated in the diagnosis of infection [34], and 
never before in VAP. In our study, MR-proADM showed 
a poor diagnostic performance for VAP.
At the day of VAP diagnosis, CPIS showed to be supe-
rior to any of the studied biomarkers. It had an excellent 
diagnostic performance, namely a high positive likeli-
hood ratio. Regarding CPIS, there is still controversy con-
cerning its widespread clinical use as a surrogate of VAP 
diagnosis since it lacks well-done studies of validation as 
well as marked inter-observer variability [35]. Besides, 
the routine use of CPIS is time-consuming and not pos-
sible to be mentally calculated; however, in the upside, it 
is an inexpensive tool.
Our study has several strengths. First, this is a multi-
center prospective observational study that limits the 
potential bias of reflecting only the practice from one 
center, as well as from retrospective data collection. Sec-
ond, we followed a group of patients ventilated for non-
infectious reasons during the first 6  days of mechanical 
ventilation. This way we could assess the kinetics of bio-
markers in VAP prediction.
Besides, we recognize that the present study has limita-
tions. First, the nonrandomized and observational nature 
of the study design bears the potential of unmeasured 
confounders that may have caused differences in thera-
peutic and supportive approach. Second, despite the use 
of quantitative cultures in VAP diagnosis, it is important 
to consider the potential false-positive and false-negative 
rates of quantitative cultures that could have influenced 
the results. Third, our findings can only be applied to 
non-infected patients admitted in the ICU for invasive 
MV and on MV for >72  h. Fourth, since measurement 
CRP was available daily in all centers and PCT in three 
centers, this could have introduced potential unmeas-
ured bias in patient classification. Finally, it is possible 
that other types of patients as well as infections, not VAP, 
may have different biomarker time courses. Thus, the 
presence of non-pulmonary infections besides VAP may 
influence the diagnostic accuracy we report in this manu-
script. Besides, our results are not applicable to patients 
that have a previous infection since we compared cases 
initially non-infected to non-infected controls.
Conclusions
In summary, we found that the combination of two 
cheap and widely available tools, CRP and CPIS, could 
be very helpful in the approach of patients undergoing 
mechanical ventilation with risk of VAP but always in 
combination with the available clinical data. On the 
one hand, we showed that the kinetics of CRP in the 
days before VAP diagnosis, namely the slope of CRP, 
could be useful in VAP prediction. A patient with 
an average increase in CRP of 1  mg/dL/day has 62  % 
greater chance of having a VAP when compared with a 
patient with no CRP increase during the first 6 days of 
mechanical ventilation. In addition, on the day of VAP, 
we could use CRP and CPIS, since CRP could be useful 
to exclude VAP diagnosis and CPIS to admit the diag-
nosis. As a result, this innovative approach needs to be 
further validated in different settings and with a larger 
sample size.
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